First Trials Set to Begin for BICX104, An Unprecedented Way for Patients to Receive Naltrexone

Published on April 28, 2022

BICX104 is a biodegradable, implantable pellet that can be used for the treatment of various substance abuse disorders.

Continue reading on website
Other news

Here's Why Choice Hotels is a Top Pick for the Rest of the Year...

April 28, 2022
Choice Hotels (CHH) is one of the top hotel stocks due to its unique business model which ensures high margins. Additionally, travel stocks will benefit from pent-up demand for travel...

Synthesis AI raises $17M to generate synthetic data for computer vision

April 28, 2022
Synthesis AI, a startup developing a platform that generates synthetic data to train AI systems, today announced that it raised $17 million in a Series A funding round led by 468 Capital with participation from Sorenson Ventures and Strawberry Creek Ventures, Bee Partners, PJC, iRobot Ventures, Boom Capital and Kubera Venture Capital. CEO and founder Yashar Behzadi says that the proceeds will be p